Research graph
References from Entering the era of disease modification in Crohn’s disease. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1053/j.gastro.2011.01.055
10.1053/j.gastro.2011.01.055 · External reference
10.1136/gutjnl-2011-301971
10.1136/gutjnl-2011-301971 · External reference
10.1093/ecco-jcc/jjab141
10.1093/ecco-jcc/jjab141 · External reference
Surgery in a Population-Based Cohort of Crohn’s Disease From Olmsted County, Minnesota (1970–2004)
10.1038/ajg.2012.298 · 2012 · External reference
10.1038/s41575-024-01035-7
10.1038/s41575-024-01035-7 · External reference
Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
10.1111/apt.18294 · 2024 · External reference
10.3390/jcm14051536
10.3390/jcm14051536 · External reference
Early Crohn’s disease: can we change the disease course?
10.1038/s41575-025-01072-w · 2025 · External reference
Rheumatoid arthritis
10.1016/s0140-6736(23)01525-8 · 2023 · External reference
10.1136/annrheumdis-2016-210602
10.1136/annrheumdis-2016-210602 · External reference
Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts
10.1136/annrheumdis-2014-206047 · 2015 · External reference
10.1136/rmdopen-2018-000870
10.1136/rmdopen-2018-000870 · External reference
Very early rheumatoid arthritis is the major predictor of major outcomes: Clinical ACR remission and radiographic non-progression
10.1136/ard.2010.142729 · 2011 · External reference
10.1093/rheumatology/keh199
10.1093/rheumatology/keh199 · External reference
10.1002/art.22353
10.1002/art.22353 · External reference
Interventional studies targeting the prodromal or preclinical phase of immune-mediated disease to benefit patient outcomes: a scoping review
10.1016/j.jaut.2026.103526 · 2026 · External reference
10.1053/j.gastro.2020.10.065
10.1053/j.gastro.2020.10.065 · External reference
10.1097/00054725-200207000-00002
10.1097/00054725-200207000-00002 · External reference
10.1038/ajg.2009.579
10.1038/ajg.2009.579 · External reference
10.1002/ibd.21417
10.1002/ibd.21417 · External reference
10.1093/ecco-jcc/jjaf203
10.1093/ecco-jcc/jjaf203 · External reference
P0472 Impact of diagnostic delay on disease progression and advanced treatment requirements in a real-world Inflammatory Bowel Disease cohort
2026 · External reference
Global patterns of disease progression in inflammatory bowel disease: a comprehensive synthesis of contemporary population-based cohorts
10.1093/gastro/goag013 · 2026 · External reference
10.1053/j.gastro.2005.12.019
10.1053/j.gastro.2005.12.019 · External reference
10.3390/jcm14227984
10.3390/jcm14227984 · External reference
10.1053/j.gastro.2020.12.031
10.1053/j.gastro.2020.12.031 · External reference
10.1053/j.gastro.2020.12.031
10.1053/j.gastro.2020.12.031 · External reference
10.1016/j.cgh.2025.10.022
10.1016/j.cgh.2025.10.022 · External reference
10.1053/j.gastro.2013.06.009
10.1053/j.gastro.2013.06.009 · External reference
10.1053/j.gastro.2013.04.048
10.1053/j.gastro.2013.04.048 · External reference
10.1016/s0140-6736(02)08512-4
10.1016/s0140-6736(02)08512-4 · External reference
10.1053/j.gastro.2006.11.041
10.1053/j.gastro.2006.11.041 · External reference
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial
10.1016/s0140-6736(08)60304-9 · 2008 · External reference
10.1093/ecco-jcc/jjy014
10.1093/ecco-jcc/jjy014 · External reference
10.1053/j.gastro.2018.01.004
10.1053/j.gastro.2018.01.004 · External reference
10.1016/j.cgh.2021.11.030
10.1016/j.cgh.2021.11.030 · External reference
10.1053/j.gastro.2008.07.069
10.1053/j.gastro.2008.07.069 · External reference
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease
10.1053/j.gastro.2005.01.048 · 2005 · External reference
10.1016/s0140-6736(15)00068-9
10.1016/s0140-6736(15)00068-9 · External reference
Treatment Pathways in Patients With Crohn’s Disease and Ulcerative Colitis: Understanding the Road to Advanced Therapy
10.1093/crocol/otae040 · 2024 · External reference
10.1093/ibd/izab228
10.1093/ibd/izab228 · External reference
Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials
10.1053/j.gastro.2021.10.037 · 2022 · External reference
A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes
10.1177/17562848221142673 · 2022 · External reference
10.1056/nejmoa0904492
10.1056/nejmoa0904492 · External reference
10.1111/apt.13139
10.1111/apt.13139 · External reference
10.1016/s0140-6736(17)32641-7
10.1016/s0140-6736(17)32641-7 · External reference
10.1053/j.gastro.2020.03.039
10.1053/j.gastro.2020.03.039 · External reference
Treat to target versus standard of care for patients with Crohn’s disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
10.1016/s2468-1253(21)00474-x · 2022 · External reference
10.1053/j.gastro.2025.02.031
10.1053/j.gastro.2025.02.031 · External reference
10.1016/j.cgh.2024.07.034
10.1016/j.cgh.2024.07.034 · External reference
10.1002/ibd.21506
10.1002/ibd.21506 · External reference
10.1016/j.cgh.2015.02.041
10.1016/j.cgh.2015.02.041 · External reference
10.1093/ecco-jcc/jjae102
10.1093/ecco-jcc/jjae102 · External reference
10.1053/j.gastro.2014.09.015
10.1053/j.gastro.2014.09.015 · External reference
10.1016/j.cgh.2017.06.053
10.1016/j.cgh.2017.06.053 · External reference
10.1016/s2468-1253(24)00034-7
10.1016/s2468-1253(24)00034-7 · External reference
Anti-tumor necrosis factor treatment from diagnosis is more effective and less costly than conventional “step-up” care for patients with active Crohn’s disease: a cost-effectiveness analysis from the PROFILE trial
10.1093/ecco-jcc/jjaf150 · 2025 · External reference
10.1016/s0140-6736(17)30317-3
10.1016/s0140-6736(17)30317-3 · External reference
10.1136/gutjnl-2020-322339
10.1136/gutjnl-2020-322339 · External reference
10.1093/ecco-jcc/jjae091
10.1093/ecco-jcc/jjae091 · External reference
10.1093/ecco-jcc/jjae089
10.1093/ecco-jcc/jjae089 · External reference
British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025
2025 · External reference
10.1093/ibd/izag073
10.1093/ibd/izag073 · External reference
10.1136/gutjnl-2024-333280
10.1136/gutjnl-2024-333280 · External reference
10.1016/j.cgh.2026.06.029
10.1016/j.cgh.2026.06.029 · External reference
10.1016/s2468-1253(24)00034-7
10.1016/s2468-1253(24)00034-7 · External reference
Vedolizumab in early and late Crohn’s disease (LOVE-CD): a phase 4 open-label cohort study
10.1016/s2468-1253(25)00233-x · 2025 · External reference
10.3390/biomedicines13020391
10.3390/biomedicines13020391 · External reference
Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
10.1016/j.gastha.2024.02.008 · 2024 · External reference
DOP060 Early disease efficacy of guselkumab therapy in biologic-naïve patients with moderately to severely active Crohn’s disease: Post-hoc analysis from the phase 3 GALAXI 2 & 3 studies
2025 · External reference
Efficacy of Upadacitinib for Moderately to Severely Active Crohn’s Disease by Disease Duration: A Post Hoc Analysis of Phase 3 Induction and Maintenance Studies
2023 · External reference
10.1016/j.coph.2025.102583
10.1016/j.coph.2025.102583 · External reference
10.1056/nejmoa2314585
10.1056/nejmoa2314585 · External reference
Vedolizumab treatment outcomes in early versus late Crohn’s disease
10.1016/s2468-1253(25)00349-8 · 2026 · External reference
10.1093/ibd/izag114
10.1093/ibd/izag114 · External reference
10.1093/ecco-jcc/jjv184
10.1093/ecco-jcc/jjv184 · External reference
10.1016/s2468-1253(17)30248-0
10.1016/s2468-1253(17)30248-0 · External reference
10.1016/s2468-1253(25)00374-7
10.1016/s2468-1253(25)00374-7 · External reference
Early Ileocecal Resection for Crohn’s Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study
10.1053/j.gastro.2023.05.051 · 2023 · External reference
Early ileal resection in Crohn’s disease is not associated with severe long‐term outcomes: The ERIC study
10.1111/apt.18247 · 2024 · External reference
Long-term comparative outcomes after ileocecal resection for inflammatory versus complicated Crohn’s disease. A multicenter, retrospective study (Crohn’s-Urg)
10.1016/j.dld.2025.07.009 · 2025 · External reference
Impact of timing of primary ileocecal resection on prognosis in patients with Crohn’s disease
2023 · External reference
Upfront medical or surgical treatment in Crohn’s disease
10.1016/s2468-1253(26)00078-6 · 2026 · External reference
Apples and oranges? Comparison of early ileocolic resection and medical treatment for Crohn’s disease: a systematic review and meta-analysis
10.1093/ecco-jcc/jjaf218 · 2025 · External reference
10.1136/gutjnl-2023-329963
10.1136/gutjnl-2023-329963 · External reference
10.1016/s2468-1253(21)00393-9
10.1016/s2468-1253(21)00393-9 · External reference
10.1016/j.cgh.2025.09.014
10.1016/j.cgh.2025.09.014 · External reference
10.1093/ecco-jcc/jjw126
10.1093/ecco-jcc/jjw126 · External reference
OP20 Results from the STENOVA trial: A Phase 2a, randomized, placebo-controlled, double-blind study to assess the safety, pharmacokinetics (PK), and pharmacodynamics of ontunisertib (AGMB-129) in patients with Fibrostenotic Crohn’s Disease (FSCD)
2026 · External reference
Methodological pitfalls in mild Crohn’s disease clinical trials
10.1016/j.medj.2026.101042 · 2026 · External reference
10.3390/jcm9082646
10.3390/jcm9082646 · External reference
Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel Disease
10.1093/ecco-jcc/jjae145 · 2025 · External reference
Seeing the whole picture: Inflammatory bowel disease complications and extraintestinal manifestations on cross‐sectional imaging
10.1002/ueg2.12619 · 2024 · External reference
10.1111/apt.70181
10.1111/apt.70181 · External reference
10.1093/ecco-jcc/jjz160
10.1093/ecco-jcc/jjz160 · External reference
Understanding and Addressing the Psychological Burden of IBD
10.1093/ecco-jcc/jjab130 · 2022 · External reference
Combination therapies: the next major frontier in IBD management
10.1038/s41575-023-00839-3 · 2023 · External reference
Redefining Early Intervention and the Window of Opportunity in Crohn’s Disease
2026 · External reference
Is Prevention the Best Way to Modify Inflammatory Bowel Disease? How Close Are We?
10.1053/j.gastro.2021.07.051 · 2022 · External reference
Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design
10.1016/s2468-1253(24)00439-4 · 2025 · External reference
Review article: Prevention of inflammatory bowel disease—The path forward
10.1111/apt.18263 · 2024 · External reference
How Should an IBD Prevention Trial Be Designed?
10.1093/ibd/izaf212 · 2025 · External reference
Patient and First-Degree Relatives Perceptions About Prediction and Prevention of Inflammatory Bowel Disease—A Multinational Survey
10.1002/ueg2.70091 · 2025 · External reference
10.1016/s2468-1253(19)30340-1
10.1016/s2468-1253(19)30340-1 · External reference
10.1136/gutjnl-2023-330000
10.1136/gutjnl-2023-330000 · External reference
10.1016/j.cgh.2024.01.026
10.1016/j.cgh.2024.01.026 · External reference
10.1016/s0140-6736(22)01193-x
10.1016/s0140-6736(22)01193-x · External reference
10.1002/art.22353
10.1002/art.22353 · ExternalCitation · doi-reference
10.1002/ibd.21417
10.1002/ibd.21417 · ExternalCitation · doi-reference
10.1002/ibd.21506
10.1002/ibd.21506 · ExternalCitation · doi-reference
Seeing the whole picture: Inflammatory bowel disease complications and extraintestinal manifestations on cross‐sectional imaging
10.1002/ueg2.12619 · ExternalCitation · doi-reference
Patient and First-Degree Relatives Perceptions About Prediction and Prevention of Inflammatory Bowel Disease—A Multinational Survey
10.1002/ueg2.70091 · ExternalCitation · doi-reference
10.1016/j.cgh.2015.02.041
10.1016/j.cgh.2015.02.041 · ExternalCitation · doi-reference
10.1016/j.cgh.2017.06.053
10.1016/j.cgh.2017.06.053 · ExternalCitation · doi-reference
10.1016/j.cgh.2021.11.030
10.1016/j.cgh.2021.11.030 · ExternalCitation · doi-reference
10.1016/j.cgh.2024.01.026
10.1016/j.cgh.2024.01.026 · ExternalCitation · doi-reference
10.1016/j.cgh.2024.07.034
10.1016/j.cgh.2024.07.034 · ExternalCitation · doi-reference
10.1016/j.cgh.2025.09.014
10.1016/j.cgh.2025.09.014 · ExternalCitation · doi-reference
10.1016/j.cgh.2025.10.022
10.1016/j.cgh.2025.10.022 · ExternalCitation · doi-reference
10.1016/j.cgh.2026.06.029
10.1016/j.cgh.2026.06.029 · ExternalCitation · doi-reference
10.1016/j.coph.2025.102583
10.1016/j.coph.2025.102583 · ExternalCitation · doi-reference
Long-term comparative outcomes after ileocecal resection for inflammatory versus complicated Crohn’s disease. A multicenter, retrospective study (Crohn’s-Urg)
10.1016/j.dld.2025.07.009 · ExternalCitation · doi-reference
Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
10.1016/j.gastha.2024.02.008 · ExternalCitation · doi-reference
Interventional studies targeting the prodromal or preclinical phase of immune-mediated disease to benefit patient outcomes: a scoping review
10.1016/j.jaut.2026.103526 · ExternalCitation · doi-reference
Methodological pitfalls in mild Crohn’s disease clinical trials
10.1016/j.medj.2026.101042 · ExternalCitation · doi-reference
10.1016/s0140-6736(02)08512-4
10.1016/s0140-6736(02)08512-4 · ExternalCitation · doi-reference
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial
10.1016/s0140-6736(08)60304-9 · ExternalCitation · doi-reference
10.1016/s0140-6736(15)00068-9
10.1016/s0140-6736(15)00068-9 · ExternalCitation · doi-reference
10.1016/s0140-6736(17)30317-3
10.1016/s0140-6736(17)30317-3 · ExternalCitation · doi-reference
10.1016/s0140-6736(17)32641-7
10.1016/s0140-6736(17)32641-7 · ExternalCitation · doi-reference
10.1016/s0140-6736(22)01193-x
10.1016/s0140-6736(22)01193-x · ExternalCitation · doi-reference
Rheumatoid arthritis
10.1016/s0140-6736(23)01525-8 · ExternalCitation · doi-reference
10.1016/s2468-1253(17)30248-0
10.1016/s2468-1253(17)30248-0 · ExternalCitation · doi-reference
10.1016/s2468-1253(19)30340-1
10.1016/s2468-1253(19)30340-1 · ExternalCitation · doi-reference
10.1016/s2468-1253(21)00393-9
10.1016/s2468-1253(21)00393-9 · ExternalCitation · doi-reference
Treat to target versus standard of care for patients with Crohn’s disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
10.1016/s2468-1253(21)00474-x · ExternalCitation · doi-reference
10.1016/s2468-1253(24)00034-7
10.1016/s2468-1253(24)00034-7 · ExternalCitation · doi-reference
Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design
10.1016/s2468-1253(24)00439-4 · ExternalCitation · doi-reference
Vedolizumab in early and late Crohn’s disease (LOVE-CD): a phase 4 open-label cohort study
10.1016/s2468-1253(25)00233-x · ExternalCitation · doi-reference
Vedolizumab treatment outcomes in early versus late Crohn’s disease
10.1016/s2468-1253(25)00349-8 · ExternalCitation · doi-reference
10.1016/s2468-1253(25)00374-7
10.1016/s2468-1253(25)00374-7 · ExternalCitation · doi-reference
Upfront medical or surgical treatment in Crohn’s disease
10.1016/s2468-1253(26)00078-6 · ExternalCitation · doi-reference
10.1038/ajg.2009.579
10.1038/ajg.2009.579 · ExternalCitation · doi-reference
Surgery in a Population-Based Cohort of Crohn’s Disease From Olmsted County, Minnesota (1970–2004)
10.1038/ajg.2012.298 · ExternalCitation · doi-reference
Combination therapies: the next major frontier in IBD management
10.1038/s41575-023-00839-3 · ExternalCitation · doi-reference
10.1038/s41575-024-01035-7
10.1038/s41575-024-01035-7 · ExternalCitation · doi-reference
Early Crohn’s disease: can we change the disease course?
10.1038/s41575-025-01072-w · ExternalCitation · doi-reference
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease
10.1053/j.gastro.2005.01.048 · ExternalCitation · doi-reference
10.1053/j.gastro.2005.12.019
10.1053/j.gastro.2005.12.019 · ExternalCitation · doi-reference
10.1053/j.gastro.2006.11.041
10.1053/j.gastro.2006.11.041 · ExternalCitation · doi-reference
10.1053/j.gastro.2008.07.069
10.1053/j.gastro.2008.07.069 · ExternalCitation · doi-reference
10.1053/j.gastro.2011.01.055
10.1053/j.gastro.2011.01.055 · ExternalCitation · doi-reference
10.1053/j.gastro.2013.04.048
10.1053/j.gastro.2013.04.048 · ExternalCitation · doi-reference
10.1053/j.gastro.2013.06.009
10.1053/j.gastro.2013.06.009 · ExternalCitation · doi-reference
10.1053/j.gastro.2014.09.015
10.1053/j.gastro.2014.09.015 · ExternalCitation · doi-reference
10.1053/j.gastro.2018.01.004
10.1053/j.gastro.2018.01.004 · ExternalCitation · doi-reference
10.1053/j.gastro.2020.03.039
10.1053/j.gastro.2020.03.039 · ExternalCitation · doi-reference
10.1053/j.gastro.2020.10.065
10.1053/j.gastro.2020.10.065 · ExternalCitation · doi-reference
10.1053/j.gastro.2020.12.031
10.1053/j.gastro.2020.12.031 · ExternalCitation · doi-reference
Is Prevention the Best Way to Modify Inflammatory Bowel Disease? How Close Are We?
10.1053/j.gastro.2021.07.051 · ExternalCitation · doi-reference
Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials
10.1053/j.gastro.2021.10.037 · ExternalCitation · doi-reference
Early Ileocecal Resection for Crohn’s Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study
10.1053/j.gastro.2023.05.051 · ExternalCitation · doi-reference
10.1053/j.gastro.2025.02.031
10.1053/j.gastro.2025.02.031 · ExternalCitation · doi-reference
10.1056/nejmoa0904492
10.1056/nejmoa0904492 · ExternalCitation · doi-reference
10.1056/nejmoa2314585
10.1056/nejmoa2314585 · ExternalCitation · doi-reference
Treatment Pathways in Patients With Crohn’s Disease and Ulcerative Colitis: Understanding the Road to Advanced Therapy
10.1093/crocol/otae040 · ExternalCitation · doi-reference
Understanding and Addressing the Psychological Burden of IBD
10.1093/ecco-jcc/jjab130 · ExternalCitation · doi-reference
10.1093/ecco-jcc/jjab141
10.1093/ecco-jcc/jjab141 · ExternalCitation · doi-reference
10.1093/ecco-jcc/jjae089
10.1093/ecco-jcc/jjae089 · ExternalCitation · doi-reference
10.1093/ecco-jcc/jjae091
10.1093/ecco-jcc/jjae091 · ExternalCitation · doi-reference
10.1093/ecco-jcc/jjae102
10.1093/ecco-jcc/jjae102 · ExternalCitation · doi-reference
Prevalence, Characteristics, Management, and Outcomes of Difficult-to-Treat Inflammatory Bowel Disease
10.1093/ecco-jcc/jjae145 · ExternalCitation · doi-reference
Anti-tumor necrosis factor treatment from diagnosis is more effective and less costly than conventional “step-up” care for patients with active Crohn’s disease: a cost-effectiveness analysis from the PROFILE trial
10.1093/ecco-jcc/jjaf150 · ExternalCitation · doi-reference
10.1093/ecco-jcc/jjaf203
10.1093/ecco-jcc/jjaf203 · ExternalCitation · doi-reference
Apples and oranges? Comparison of early ileocolic resection and medical treatment for Crohn’s disease: a systematic review and meta-analysis
10.1093/ecco-jcc/jjaf218 · ExternalCitation · doi-reference
10.1093/ecco-jcc/jjv184
10.1093/ecco-jcc/jjv184 · ExternalCitation · doi-reference
10.1093/ecco-jcc/jjw126
10.1093/ecco-jcc/jjw126 · ExternalCitation · doi-reference
10.1093/ecco-jcc/jjy014
10.1093/ecco-jcc/jjy014 · ExternalCitation · doi-reference
10.1093/ecco-jcc/jjz160
10.1093/ecco-jcc/jjz160 · ExternalCitation · doi-reference
Global patterns of disease progression in inflammatory bowel disease: a comprehensive synthesis of contemporary population-based cohorts
10.1093/gastro/goag013 · ExternalCitation · doi-reference
10.1093/ibd/izab228
10.1093/ibd/izab228 · ExternalCitation · doi-reference
How Should an IBD Prevention Trial Be Designed?
10.1093/ibd/izaf212 · ExternalCitation · doi-reference
10.1093/ibd/izag073
10.1093/ibd/izag073 · ExternalCitation · doi-reference
10.1093/ibd/izag114
10.1093/ibd/izag114 · ExternalCitation · doi-reference
10.1093/rheumatology/keh199
10.1093/rheumatology/keh199 · ExternalCitation · doi-reference
10.1097/00054725-200207000-00002
10.1097/00054725-200207000-00002 · ExternalCitation · doi-reference
10.1111/apt.13139
10.1111/apt.13139 · ExternalCitation · doi-reference
Early ileal resection in Crohn’s disease is not associated with severe long‐term outcomes: The ERIC study
10.1111/apt.18247 · ExternalCitation · doi-reference
Review article: Prevention of inflammatory bowel disease—The path forward
10.1111/apt.18263 · ExternalCitation · doi-reference
Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
10.1111/apt.18294 · ExternalCitation · doi-reference
10.1111/apt.70181
10.1111/apt.70181 · ExternalCitation · doi-reference
Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts
10.1136/annrheumdis-2014-206047 · ExternalCitation · doi-reference
10.1136/annrheumdis-2016-210602
10.1136/annrheumdis-2016-210602 · ExternalCitation · doi-reference
Very early rheumatoid arthritis is the major predictor of major outcomes: Clinical ACR remission and radiographic non-progression
10.1136/ard.2010.142729 · ExternalCitation · doi-reference
10.1136/gutjnl-2011-301971
10.1136/gutjnl-2011-301971 · ExternalCitation · doi-reference
10.1136/gutjnl-2020-322339
10.1136/gutjnl-2020-322339 · ExternalCitation · doi-reference
10.1136/gutjnl-2023-329963
10.1136/gutjnl-2023-329963 · ExternalCitation · doi-reference
10.1136/gutjnl-2023-330000
10.1136/gutjnl-2023-330000 · ExternalCitation · doi-reference
10.1136/gutjnl-2024-333280
10.1136/gutjnl-2024-333280 · ExternalCitation · doi-reference
10.1136/rmdopen-2018-000870
10.1136/rmdopen-2018-000870 · ExternalCitation · doi-reference
A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes
10.1177/17562848221142673 · ExternalCitation · doi-reference
10.3390/biomedicines13020391
10.3390/biomedicines13020391 · ExternalCitation · doi-reference
10.3390/jcm14051536
10.3390/jcm14051536 · ExternalCitation · doi-reference
10.3390/jcm14227984
10.3390/jcm14227984 · ExternalCitation · doi-reference
10.3390/jcm9082646
10.3390/jcm9082646 · ExternalCitation · doi-reference
